Back to Search
SHADI HALABI, MD, MPH
MD, MPH
Interventional Cardiology Physician
NPI: 1306285051IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
57022433(OH)
Interventional Cardiology PhysicianPrimary
Internal Medicine — Interventional Cardiology
Code: 207RI0011X
01086931A(IN)
CMS Specialties
PrimaryINTERVENTIONAL CARDIOLOGY
Education
OTHER
Class of 2012
Research & Publications (20)
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
PMID 19633053·Ann Oncol·2010
8-other
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
PMID 19380448·J Clin Oncol·2009
8-other
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
PMID 18487572·J Clin Oncol·2008
4-observational
Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.
PMID 17665494·Cancer·2007
4-observational
The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
PMID 17222627·J Urol·2007
8-other
Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.
PMID 16753374·J Urol·2006
4-observational
Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
PMID 15302462·Urology·2004
1-meta
Sample size determination for comparing several survival curves with unequal allocations.
PMID 15160409·Stat Med·2004
8-other
Analysis of survival data with missing measurements of a time-dependent binary covariate.
PMID 12729393·J Biopharm Stat·2003
8-other
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.
PMID 12560440·J Clin Oncol·2003
8-other
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
PMID 12663709·J Clin Oncol·2003
8-other
Progressive dyspnea in a 49-year-old woman with long-standing epilepsy.
PMID 12114381·Chest·2002
5-case
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.
PMID 19589569·Urology·2010
8-other
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
PMID 18574490·Prostate Cancer Prostatic Dis·2009
8-other
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
PMID 19211452·J Natl Cancer Inst·2009
1-meta
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
PMID 19168670·Ann Oncol·2009
3-trial
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
PMID 18936475·J Clin Oncol·2008
3-trial
Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans.
PMID 18945689·Am J Epidemiol·2008
8-other
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
PMID 18824434·Clin Genitourin Cancer·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 2160 S 1ST AVE
MAYWOOD, IL 60153 - Phone
- (708) 216-9000
Quick Facts
- NPI
- 1306285051
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 14
- Publications
- 20
Are you this provider?
Claim Your Profile